Skip to main content
Premium Trial:

Request an Annual Quote

Tm Bioscience Approves More Stock Options

Premium

TORONTO--Tm Bioscience here, which designs, develops, and commercializes DNA products for bioinformatics, functional genomics, and other uses, has auth orized the issuance of an additional 340,000 stock purchase op tions, subject to approval by the Vancouver Stock Exchange. The options vest over four years and expire on August 26, 2001. They have been awarded to recently appointed executives and employees.

Filed under

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.